Biopharmaceutical company Ampio Pharmaceuticals Inc (NYSE American:AMPE) reported on Monday the receipt of US Food and Drug Administration (FDA) Investigational New Drug (IND) approval to proceed with clinical trials of the inhaled Ampion for respiratory distress due to COVID-19 infection following the successful Phase I trial that administered Ampion intravenously to COVID-19 patients.
Under a multi-centre, randomized, controlled Phase I trial in a total of 40 patients, the company said it will assess the safety and efficacy of inhaled Ampion added to the standard of care (SOC) for COVID-19 infected patients hospitalized for respiratory distress. Ampion will be delivered by inhalation, allowing the drug to directly target and attenuate inflammation in the lungs that can lead to respiratory failure.
The company said the approved clinical trial will study the effects of inhaled Ampion throughout the clinical progression of COVID-19 infection. It will be delivered by a hand-held nebulizer for inhalation in patients with less severe cases of respiratory illness and through mechanical ventilators for inhalation in patients with severe respiratory distress syndrome (ARDS).
In conjunction, Ampion's anti-inflammatory biologic is reported to be safe and well-tolerated with no serious drug related adverse events across all clinical trials, concluded the company.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review